+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global PD-1 and PD-L1 Inhibitors Market 2019-2023 - Product Image

Global PD-1 and PD-L1 Inhibitors Market 2019-2023

  • ID: 4749699
  • Report
  • January 2019
  • Region: Global
  • 116 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer
  • MORE
Special drug designations to drive the market growth. One of the major benefits that some of the PD-1 and PD-L1 inhibitors have is the special drug designations given by the regulatory bodies. Many of these drugs have received designations such as breakthrough designation and fast track designation from the US FDA, the EMA and other regulatory bodies. Vendors who have received these designations for their molecules will get certain benefits. The analysts have predicted that the PD-1 and PD-L1 inhibitors market will register a CAGR of over 19% by 2023.

Market Overview

Increasing prevalence of cancer

Globe yearly prevalence of cancer has seen a significant rise in recent years, and the global oncology therapeutics market has witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors.

Failures in clinical trials

The global pharmaceuticals market has witnessed a significant increase in the number of trials being conducted for checkpoint inhibitors in recent years. The top six drugs that are currently approved are also in the clinical stages for the treatment of various other cancers.

For the detailed list of factors that will drive and challenge the growth of the PD-1 and PD-L1 inhibitors market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer, the competitive environment is quite intense. Factors such as the special drug designations and the increasing prevalence of cancer, will provide considerable growth opportunities to PD-1 and PD-L1 inhibitors manufacturers. AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, and Pfizer are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Solid tumors - Market size and forecast 2018-2023
  • Blood-related tumors - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Solid tumors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Approved PD-1 and PD-L1 inhibitors for various indications: Overview
Exhibit 22: Solid tumors - Year-over-year growth 2019-2023 (%)
Exhibit 23: Blood-related tumors - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Blood-related tumors - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by application
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: New cases of cancer in US 2015
Exhibit 41: Impact of drivers and challenges
Exhibit 42: PD-1 and PD-L1 inhibitors pipeline: Overview
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca - Vendor overview
Exhibit 49: AstraZeneca - Business segments
Exhibit 50: AstraZeneca - Organizational developments
Exhibit 51: AstraZeneca - Geographic focus
Exhibit 52: AstraZeneca - Key offerings
Exhibit 53: AstraZeneca - Key customers
Exhibit 54: Bristol-Myers Squibb - Vendor overview
Exhibit 55: Bristol-Myers Squibb - Business segments
Exhibit 56: Bristol-Myers Squibb - Organizational developments
Exhibit 57: Bristol-Myers Squibb - Geographic focus
Exhibit 58: Bristol-Myers Squibb - Key offerings
Exhibit 59: Bristol-Myers Squibb - Key customers
Exhibit 60: F. Hoffmann-La Roche - Vendor overview
Exhibit 61: F. Hoffmann-La Roche - Business segments
Exhibit 62: F. Hoffmann-La Roche - Organizational developments
Exhibit 63: F. Hoffmann-La Roche - Geographic focus
Exhibit 64: F. Hoffmann-La Roche - Segment focus
Exhibit 65: F. Hoffmann-La Roche - Key offerings
Exhibit 66: F. Hoffmann-La Roche - Key customers
Exhibit 67: Merck - Vendor overview
Exhibit 68: Merck - Business segments
Exhibit 69: Merck - Organizational developments
Exhibit 70: Merck - Geographic focus
Exhibit 71: Merck - Segment focus
Exhibit 72: Merck - Key customers
Exhibit 73: Pfizer - Vendor overview
Exhibit 74: Pfizer - Business segments
Exhibit 75: Pfizer - Organizational developments
Exhibit 76: Pfizer - Geographic focus
Exhibit 77: Pfizer - Segment focus
Exhibit 78: Pfizer - Key offerings
Exhibit 79: Pfizer - Key customers
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer
  • MORE
Global PD-1 and PD-L1 Inhibitors Market 2019-2023

The analyst recognizes the following companies as the key players in the global PD-1 and PD-L1 inhibitors market: AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the special drug designations.”

According to the report, one of the major drivers for this market is the increasing prevalence of cancer
.

Further, the report states that one of the major factors hindering the growth of this market is the failures in clinical trials.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll